SUMMARY

macimorelin acetate

GHRYVELIN 60 mg,

granules for oral suspension in sachet

First assessment

Original French opinion adopted by the Transparency Committee on
5 April 2023

The legally binding text is the original French opinion version

Key points

Favourable opinion on reimbursement under “this medicinal product is for diagnostic use only. GHRYVELIN is indicated for the diagnosis of growth hormone (GHD) deficiency in adults.”

What therapeutic improvement?

No improvement in management strategy.

Role in the care pathway?

In view of its advantages in terms of administration taken orally as a single dose and of the reduced constraints for the patient post-administration (in terms of number of blood samples necessary, monitoring, tolerance), but insofar as the available clinical data do not allow its preferment relative to the insulin tolerance test (ITT, reference test), GHRYVELIN (macimorelin acetate) is an option for the diagnosis of growth hormone deficiency (GHD) in adults, in the same way as the ITT.

Transparency Committee's Conclusions

Clinical Benefit

- ➔ Growth hormone deficiency in adults, documented by a single dynamic test demonstrating the somatotropin deficiency, is a disease with varied origins, rare, serious, with a morbidity (metabolic syndrome, cardiovascular complications, osteoporosis, muscle wasting), which can lead to a deterioration in quality of life.
- ➔ It is a diagnostic medicinal product.
- ➔ The diagnostic efficacy/adverse effect ratio is moderate.
- ➔ GHRYVELIN (macimorelin acetate) is an option for the diagnosis of growth hormone deficiency (GHD) in adults, in the same way as the ITT (see. 5.1).

➔ Public health benefit

In view:

- of the gravity of the disease and its rarity,
- of the partially met medical need,
- of the partial response to the need identified with:
- an absence of additional proven impact on morbidity and mortality, an additional impact being expected, but not demonstrated on quality of life,
- an additional proven impact of GHRYVELIN (macimorelin acetate), in terms of tolerance,
- an additional impact expected on the organisation of care and on the improvement in the care pathway, in view of the administration and monitoring methods following the administration of the GHRYVELIN (macimorelin acetate) test.

GHRYVELIN (macimorelin acetate) is not liable to have an additional impact on public health.

In view of all of these elements, the Committee considers that the clinical benefit provided by GHRYVELIN (macimorelin acetate) is moderate in the MA indication.

The Committee gives a favourable opinion on the inclusion of GHRYVELIN (macimorelin acetate) on the list of medicinal products approved for the use of communities in the indication and at the MA doses.

Clinical Added Value

In view:

- of the absence of demonstration of the equivalence of GHRYVELIN (macimorelin acetate) compared to the ITT reference test in the diagnosis of GHD in adults, in the study AEZS-130-052 which randomised 157 patients likely to suffer from GHD or healthy controls. In this study, the macimorelin stimulation test did not show sufficient agreement. The performance of the macimorelin test could not be judged acceptable as the lower limit of the two-sided 95% confidence interval was <70 % for one of the 2 co-primary endpoints, namely the positive percentage agreement.
- of the fact that the validity of GHRYVELIN (macimorelin acetate) was not demonstrated in the AEZS-130-047 study conducted in 80 patients with GHD or controls. In fact, the lower limit of the 99% CI of the ASC of the ROC curve, obtained by "boot-strapping" data from 10,000 samples, 83.5%, was not compliant with the current criterion of ≥ 85 % for this parameter. The methodological quality of this study was limited, particularly because of numerous amendments and post-hoc analyses,
- of the tolerance profile of GHRYVELIN (macimorelin acetate) marked by dysgeusia, fatigue and nausea, favourable compared to the comparator ITT in the AEZS-130-052 study. However, GHRYVELIN (macimorelin acetate) causes a lengthening of almost 11 ms of the corrected QT interval (QTc) the mechanism of which is unknown,
- of the absence of a gold standard in the diagnosis of GHD in adults,

the Committee considers that GHRYVELIN (macimorelin acetate) provides no clinical added value (CAV V) compared to the insulin tolerance test (ITT).